106 related articles for article (PubMed ID: 36432660)
21. Activation of Human Peripheral Basophils in Response to High IgE Antibody Concentrations without Antigens.
Yanase Y; Matsuo Y; Kawaguchi T; Ishii K; Tanaka A; Iwamoto K; Takahagi S; Hide M
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30583496
[TBL] [Abstract][Full Text] [Related]
22. Basophil Activation Test: Old and New Applications in Allergy.
Hemmings O; Kwok M; McKendry R; Santos AF
Curr Allergy Asthma Rep; 2018 Nov; 18(12):77. PubMed ID: 30430289
[TBL] [Abstract][Full Text] [Related]
23. Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro.
Neun BW; Barenholz Y; Szebeni J; Dobrovolskaia MA
Molecules; 2018 Jul; 23(7):. PubMed ID: 30002298
[TBL] [Abstract][Full Text] [Related]
24. Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems.
Liptrott NJ; Giardiello M; McDonald TO; Rannard SP; Owen A
J Nanobiotechnology; 2018 Mar; 16(1):22. PubMed ID: 29544545
[TBL] [Abstract][Full Text] [Related]
25. Human mast cells and basophils-How are they similar how are they different?
Varricchi G; Raap U; Rivellese F; Marone G; Gibbs BF
Immunol Rev; 2018 Mar; 282(1):8-34. PubMed ID: 29431214
[TBL] [Abstract][Full Text] [Related]
26. Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population.
Benasutti H; Wang G; Vu VP; Scheinman R; Groman E; Saba L; Simberg D
Bioconjug Chem; 2017 Nov; 28(11):2747-2755. PubMed ID: 29090582
[TBL] [Abstract][Full Text] [Related]
27. Histamine Release from Mast Cells and Basophils.
Borriello F; Iannone R; Marone G
Handb Exp Pharmacol; 2017; 241():121-139. PubMed ID: 28332048
[TBL] [Abstract][Full Text] [Related]
28. Positive CD63 Basophil Activation Tests Are Common in Children with Chronic Spontaneous Urticaria and Linked to High Disease Activity.
Netchiporouk E; Moreau L; Rahme E; Maurer M; Lejtenyi D; Ben-Shoshan M
Int Arch Allergy Immunol; 2016; 171(2):81-88. PubMed ID: 27846634
[TBL] [Abstract][Full Text] [Related]
29. Materials design at the interface of nanoparticles and innate immunity.
Szeto GL; Lavik EB
J Mater Chem B; 2016 Mar; 4(9):1610-1618. PubMed ID: 27453783
[No Abstract] [Full Text] [Related]
30. Recent Developments of Liposomes as Nanocarriers for Theranostic Applications.
Xing H; Hwang K; Lu Y
Theranostics; 2016; 6(9):1336-52. PubMed ID: 27375783
[TBL] [Abstract][Full Text] [Related]
31. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction.
Hoshyar N; Gray S; Han H; Bao G
Nanomedicine (Lond); 2016 Mar; 11(6):673-92. PubMed ID: 27003448
[TBL] [Abstract][Full Text] [Related]
32. Liposome-based Formulation for Intracellular Delivery of Functional Proteins.
Chatin B; Mével M; Devallière J; Dallet L; Haudebourg T; Peuziat P; Colombani T; Berchel M; Lambert O; Edelman A; Pitard B
Mol Ther Nucleic Acids; 2015 Jun; 4():e244. PubMed ID: 26102064
[TBL] [Abstract][Full Text] [Related]
33. Influence of cholesterol on liposome stability and on in vitro drug release.
Briuglia ML; Rotella C; McFarlane A; Lamprou DA
Drug Deliv Transl Res; 2015 Jun; 5(3):231-42. PubMed ID: 25787731
[TBL] [Abstract][Full Text] [Related]
34. Liposomes as nanomedical devices.
Bozzuto G; Molinari A
Int J Nanomedicine; 2015; 10():975-99. PubMed ID: 25678787
[TBL] [Abstract][Full Text] [Related]
35. Anaphylaxis to pegylated liposomal Doxorubicin: a case report.
Sharma LR; Subedi A; Shah BK
West Indian Med J; 2014 Aug; 63(4):376-7. PubMed ID: 25429486
[TBL] [Abstract][Full Text] [Related]
36. Cryptic epitopes of albumin determine mononuclear phagocyte system clearance of nanomaterials.
Mortimer GM; Butcher NJ; Musumeci AW; Deng ZJ; Martin DJ; Minchin RF
ACS Nano; 2014 Apr; 8(4):3357-66. PubMed ID: 24617595
[TBL] [Abstract][Full Text] [Related]
37. Update on the performance and application of basophil activation tests.
McGowan EC; Saini S
Curr Allergy Asthma Rep; 2013 Feb; 13(1):101-9. PubMed ID: 23188565
[TBL] [Abstract][Full Text] [Related]
38. Particulate systems for targeting of macrophages: basic and therapeutic concepts.
Moghimi SM; Parhamifar L; Ahmadvand D; Wibroe PP; Andresen TL; Farhangrazi ZS; Hunter AC
J Innate Immun; 2012; 4(5-6):509-28. PubMed ID: 22722900
[TBL] [Abstract][Full Text] [Related]
39. Marked differences in the signaling requirements for expression of CD203c and CD11b versus CD63 expression and histamine release in human basophils.
MacGlashan D
Int Arch Allergy Immunol; 2012; 159(3):243-52. PubMed ID: 22722613
[TBL] [Abstract][Full Text] [Related]
40. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.
Duggan ST; Keating GM
Drugs; 2011 Dec; 71(18):2531-58. PubMed ID: 22141391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
